The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Potential for Glembatumumab Vedotin in TNBC

Linda T. Vahdat, MD, PhD
Published Online: 12:25 AM, Fri December 9, 2016


Linda T. Vahdat, MD, PhD, ‎Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the ongoing METRIC trial and the potential for glembatumumab vedotin as a treatment for patients with triple-negative breast cancer (TNBC).

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.